Abstract 174TiP
Background
Precision cancer therapy has the potential to revolutionize treatment outcome. While genomic analysis has become central to cancer personalized medicine, recent studies have shown that it can improves survival in only a minority of the patients. Additionally, genomic mutations may suggest several treatment protocols without elucidating which approach will yield the best clinical response. To advance cancer precision guidance, we have developed cResponse®, a combined genomic-functional drug sensitivity platform to determine individualized patient treatment regimens. Fresh patient cancer samples are taken by biopsy or resection and sectioned into 250uM slices which demonstrate similar architecture and tissue proliferation to those found in vivo. An initial clinical study showed that cResponse® can preserve human cancer tissue in 3D culture together with its microenvironment, including endothelial and immune cells, at a high viability (>90%) with continued cell division for more than 7 days. On a cohort of 34 patients treated with neoadjuvant therapy or systemic therapy for metastatic disease, the assay was able to predict patient response to drug treatment with a sensitivity of 96% and a specificity of 77.7%.
Trial Design
To further validate the capacity of cResponse® to predict patient response to cancer therapy, a follow up pivotal clinical study was established in the UK with the goal of recruiting a total of 170 patients to provide a large statistical validation of the previous results. Patient cancer samples were received and evaluated with the intended to treat therapy, and their cResponse® score was matched to their RECIST data to establish sensitivity, specificity, PPV and NPV. Here we report on the outcome of the first cohort of patients recruited to the pivotal trial, confirming the ability of the platform to accurately preserve a patients cancer tissue with intact tumor microenvironment for 5 days and describing the predictive results correlated to patient response.
Editorial acknowledgement
Clinical trial identification
NCT04599608; Last update posted 2020-10-22.
Legal entity responsible for the study
Curesponse.
Funding
Curesponse.
Disclosure
S. Hanks, N. Costelloe, S. Salpeter, V. Bar, A. Zundelevich: Financial Interests, Personal, Other, Employee: Curesponse.G. Neev, R. Straussman: Financial Interests, Personal, Leadership Role: Curesponse. All other authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract